ASTAR
LIVE

Serial Number

87447655

Owner

Q-linea AB

Attorney

Donna J. Bunton

Filing Date

May 12, 2017

Add to watchlist:

No watchlists yet
View on USPTO

ASTAR Trademark

Serial Number: 87447655 • Registration: 5748159

ASTAR is a trademark filed by Q-linea AB on May 12, 2017. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Q-linea AB (8 trademarks)

Dag Hammarskjölds väg 52 A

Entity Type: 99

Trademark Details

Filing Date

May 12, 2017

Registration Date

May 14, 2019

Published for Opposition

December 18, 2018

Goods & Services

(Based on 44(e)) Apparatus for detection and analysis of microbes in biological samples for medical use; medical diagnostic instruments for testing for microbes in human and veterinary body fluids; diagnostic apparatus, for medical diagnostics for testing for infectious diseases and antimicrobial susceptibility; diagnostic apparatus for medical purposes for use in diagnosing infectious diseases; diagnostic, examination, and monitoring equipment which operates via time-lapse imaging for antimicrobial susceptibility testing all being for medical purposes; diagnostic testing apparatus for detecting, identification and analysis of microbes for medical purposes; none of the aforesaid being for use in the design or creation of personalized joint replacement technologies or for interfacing with living tissue, namely, stimulating, acquiring, recording, analyzing and using signals from the brain, nervous system and related structures

(Based on 44(e)) Scientific, optical, measuring, and checking apparatus and instruments for microbe detection, identification and susceptibility determination, identification, analyzing and testing, namely, fluidics and time-lapse imaging apparatus not for medical purposes; scientific research and laboratory apparatus for microbe detection and susceptibility determination, identification, analyzing and testing, namely, for fluidics and time-lapse imaging; laboratory instruments, namely, fluidics and time-lapse imaging devices for the detection of pathogens in a biological sample for research use; diagnostic apparatus, not for medical purposes, for microbe detection and susceptibility determination, identification, analyzing and testing for laboratory or research use; software for analyzing pathogen and susceptibility detection, identification, analyzing and testing for microbe detection and susceptibility determination; measuring apparatus and instruments, namely, pathogen growth measuring instruments not for medical purposes

(Based on 44(e)) diagnostic preparations for medical and veterinary purposes; medical diagnostic reagents; clinical diagnostic reagents for medical and veterinary purposes; diagnostic preparations for medical purposes

(Based on 44(e)) Diagnostic preparations for scientific or research use; diagnostic reagents for scientific or research use; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; reagents for use in scientific apparatus for chemical or biological analysis; chemical preparations for scientific purposes, other than for medical or veterinary use; diagnostic preparations for scientific or research use other than for medical use; nucleic acids for laboratory, scientific or research use; nucleic acid for use in nucleic acid amplification processes other than for medical and veterinary use; nucleic acid amplification reagents other than for medical and veterinary use; nucleic acid sequencing programs other than for medical and veterinary use; nucleic acid sequences, other than for medical or veterinary purposes; chemicals for use in multiplying nucleic acid amounts other than medical and veterinary use; diagnostic kits comprising specimen receptors and reagents for testing for selected bacteria; diagnostic preparations for scientific purposes; chemical products for scientific diagnostic use; chemical diagnostic reagents for industrial use; diagnostic preparations, other than for medical or veterinary purposes

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Feb 19, 2026 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Feb 19, 2026 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Feb 19, 2026 APRE
TEAS SECTION 8 & 15 RECEIVED
Nov 14, 2025 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
May 14, 2024 REM1
REGISTERED-PRINCIPAL REGISTER
May 14, 2019 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Apr 9, 2019 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 9, 2019 AITU
NOTICE OF ALLOWANCE CANCELLED
Mar 20, 2019 IUCN
TEAS POST PUBLICATION AMENDMENT RECEIVED
Mar 20, 2019 EPPA
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 12, 2019 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 18, 2018 NPUB
PUBLISHED FOR OPPOSITION
Dec 18, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 28, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 8, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 7, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 6, 2018 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Nov 6, 2018 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 3, 2018 GNFN
FINAL REFUSAL E-MAILED
Sep 3, 2018 GNFR
FINAL REFUSAL WRITTEN
Sep 3, 2018 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 9, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 8, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 8, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 9, 2018 GNRN
NON-FINAL ACTION E-MAILED
Feb 9, 2018 GNRT
NON-FINAL ACTION WRITTEN
Feb 9, 2018 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 18, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 18, 2018 CRFA
ASSIGNED TO LIE
Jan 11, 2018 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 22, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 26, 2017 GNRN
NON-FINAL ACTION E-MAILED
Jun 26, 2017 GNRT
NON-FINAL ACTION WRITTEN
Jun 26, 2017 CNRT
ASSIGNED TO EXAMINER
Jun 22, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 17, 2017 NWOS
NEW APPLICATION ENTERED
May 16, 2017 NWAP